dermatology
Skin cancers

Targeted therapy for stage III melanoma on the PBS

The combination of dabrafenib and trametinib (Tafinlar and Mekinist) will be added to the PBS from November 1 for adjuvant treatment of patients with completely resected BRAF V600 mutation positive Stage IIIB, IIIC or IIID malignant melanoma. Patients with Stage III resected melanoma who may be eligible for the adjuvant treatment will also have MBS ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic